Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.50 |
| ▸ | MMP1 | P03956 | 7/20 | 0.50 |
| ▸ | MMP9 | P14780 | 7/20 | 0.50 |
| ▸ | MMP13 | P45452 | 7/20 | 0.50 |
| ▸ | MMP3 | P08254 | 6/20 | 0.50 |
| ▸ | MMP7 | P09237 | 6/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13507008 | 0.81 | MMP2 (0.55) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL6324074 | 0.80 | MMP2 (0.53) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3416060 | 0.80 | MMP2 (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3161450 | 0.80 | MMP2 (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL6324072 | 0.80 | MMP2 (0.53) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL6321461 | 0.80 | MMP2 (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3925403 | 0.77 | MMP2 (0.50) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3153329 | 0.77 | MMP2 (0.50) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3156061 | 0.77 | MMP2 (0.50) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3017227 | 0.77 | MMP2 (0.60) | MMP2MMP1MMP9MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | MMP2 4274/4885MMP1 3376/4885MMP9 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.